Anti-amyloid Alzheimer's drugs don't deliver the breakthrough patients deserve — an extensive review of 17 clinical trials found their effects on cognitive decline are trivial, and functional improvements are small at best. Lumping failed drugs with newer ones skews the picture, but even lecanemab and donanemab only slow decline by months. That's not a gamechangergame-changer — that's a consolation prize dressed up as a cure.